Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of AZD5718 in Healthy Male Subjects
NCT02632526Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of atuliflapon in coronary artery disease (CAD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants With Adverse Events up to 8 weeks. Started Feb 2016; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02632526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632526.